RXRX vs RLAY
RXRX and RLAY side by side — valuation & fundamentals (public data).
Key statistics
| Metric | RXRXRECURSION PHARMACEUTICALS, INC. | RLAYRelay Therapeutics, Inc. |
|---|---|---|
| Market cap | — | $3.59B |
| P/S | — | 226.8x |
| Revenue growth (YoY) | 26.9% | 53.4% |
| Earnings growth (YoY) | -39.1% | 18.1% |
| EBIT margin | -867.9% | -1971.6% |
| ROE | -62.9% | -43.1% |
| ROIC | -174.7% | — |
| 1y total return | -45.4% | +439.5% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: RXRX frente a RLAY
| Métrica | RXRX | RLAY |
|---|---|---|
| Valor final | $990 | $5.7K |
| Retorno total | -90.1% | -42.7% |
| CAGR | -35.4% | -10.0% |
| Volatilidad | 92.9% | 77.2% |
| Sharpe | -0.07 | 0.19 |
| Sortino | -0.11 | 0.29 |
| Caída máxima | -93.1% | -94.7% |
Basado en 1330 días de negociación comunes, 2021-04-16 → 2026-08-03 · tasa libre de riesgo 3.83% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)